Figure 2 | British Journal of Cancer

Figure 2

From: Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells

Figure 2

Effect of gefitinib alone on the cell growth of five human breast cancer cell lines tested. Semiconfluent cells were cultured for 2 days in the oestrogen-deprived medium with vehicle, 0.1, 1.0, 10, 20 or 30 μ M gefitinib. After cell dispersion, the cell numbers were measured with a Coulter counter. Triplicate wells were treated in each experiment. Values represent means±s.e. , KPL-1; •- - -•, KPL-3C; , T47D; ○- - -○, KPL-4; and ○—○, MDA-MB-231.

Back to article page